Research Paper Volume 13, Issue 8 pp 11528—11541

MicroRNA-532-5p protects against cerebral ischemia-reperfusion injury by directly targeting CXCL1

OGD/R treatment increased methylation of the miR-532-5p promoter. (A, B) Methylation-specific PCR (MSP) results show the methylation status of the CpG islands in the miR-532-5p promoter sequence in SH-SY5Y cells treated with OGD/R, 5-Aza or OGD/R + 5-Aza and untreated controls. ‘U’ refers to PCR with primers specific to unmethylated sequence and ‘M’ refers to PCR with primers specific to methylated sequence. (C) RT-qPCR analysis shows the relative expression levels of miR-532-5p in SH-SY5Y cells treated with OGD/R, 5-Aza or OGD/R + 5-Aza and untreated controls. (D) RT-qPCR analysis shows the relative expression levels of CXCL1 mRNA in SH-SY5Y cells treated with OGD/R, 5-Aza or OGD/R + 5-Aza compared to untreated controls. **P #P ##P

Figure 5. OGD/R treatment increased methylation of the miR-532-5p promoter. (A, B) Methylation-specific PCR (MSP) results show the methylation status of the CpG islands in the miR-532-5p promoter sequence in SH-SY5Y cells treated with OGD/R, 5-Aza or OGD/R + 5-Aza and untreated controls. ‘U’ refers to PCR with primers specific to unmethylated sequence and ‘M’ refers to PCR with primers specific to methylated sequence. (C) RT-qPCR analysis shows the relative expression levels of miR-532-5p in SH-SY5Y cells treated with OGD/R, 5-Aza or OGD/R + 5-Aza and untreated controls. (D) RT-qPCR analysis shows the relative expression levels of CXCL1 mRNA in SH-SY5Y cells treated with OGD/R, 5-Aza or OGD/R + 5-Aza compared to untreated controls. **P < 0.01 compared to control; #P < 0.05, ##P < 0.01 compared to OGD/R. All experiments were performed in triplicate.